Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Archives of General Psychiatry
Paolo Fusar-PoliPhilip K McGuire

Abstract

Cannabis use can both increase and reduce anxiety in humans. The neurophysiological substrates of these effects are unknown. To investigate the effects of 2 main psychoactive constituents of Cannabis sativa (Delta9-tetrahydrocannabinol [Delta9-THC] and cannabidiol [CBD]) on regional brain function during emotional processing. Subjects were studied on 3 separate occasions using an event-related functional magnetic resonance imaging paradigm while viewing faces that implicitly elicited different levels of anxiety. Each scanning session was preceded by the ingestion of either 10 mg of Delta9-THC, 600 mg of CBD, or a placebo in a double-blind, randomized, placebo-controlled design. Fifteen healthy, English-native, right-handed men who had used cannabis 15 times or less in their life. Regional brain activation (blood oxygenation level-dependent response), electrodermal activity (skin conductance response [SCR]), and objective and subjective ratings of anxiety. Delta9-Tetrahydrocannabinol increased anxiety, as well as levels of intoxication, sedation, and psychotic symptoms, whereas there was a trend for a reduction in anxiety following administration of CBD. The number of SCR fluctuations during the processing of intensely fearful f...Continue Reading

Associated Clinical Trials

Apr 5, 2021·Jennifer L. Robinson, Ph.D.

Citations

Jun 17, 2009·Psychopharmacology·Dagmar KoetheF Markus Leweke
Jul 10, 2013·Psychopharmacology·Max SpadernaDeepak Cyril D'Souza
Jul 21, 2011·European Archives of Psychiatry and Clinical Neuroscience·Lorenzo SomainiGilberto Gerra
Jul 25, 2009·Psychological Medicine·R Martín-SantosP McGuire
Aug 30, 2012·European Journal of Clinical Nutrition·S BorgwardtC Beglinger
Nov 20, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sagnik BhattacharyyaPhilip K McGuire
Mar 18, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Toby T Winton-BrownPhilip K McGuire
Sep 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrés Uribe-MariñoNorberto Cysne Coimbra
Feb 11, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mateus M BergamaschiJosé Alexandre S Crippa
Oct 4, 2011·Schizophrenia Bulletin·Stephan F TaylorUNKNOWN Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia
May 16, 2012·Journal of Psychopharmacology·Michael E BallardHarriet de Wit
Jan 30, 2014·Annual Review of Clinical Psychology·Ruud van Winkel, Rebecca Kuepper
Sep 24, 2013·Neurobiology of Learning and Memory·Christine A RabinakK Luan Phan
Aug 9, 2011·Psychopharmacology·Hendrika H van HellNick F Ramsey
Dec 14, 2011·Journal of Neural Transmission·Christine A RabinakK Luan Phan
Apr 1, 2011·Expert Opinion on Drug Discovery·Radu TanasescuCris S Constantinescu
Dec 29, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Margaret HaneySharon L Walsh
Mar 13, 2016·Biological Psychiatry·Mohamed SherifMohini Ranganathan
May 28, 2013·Journal of Pain and Symptom Management·Paul HowardAndrew Wilcock
Sep 18, 2012·Journal of Psychiatric Research·Alline Cristina CamposFrancisco Silveira Guimarães
Jul 28, 2012·Psychiatry Research·Melissa P Lopez-LarsonDeborah A Yurgelun-Todd
Jan 29, 2011·The Journal of Sexual Medicine·Rany Shamloul, Anthony J Bella
Mar 17, 2012·Behavioural Brain Research·Lauren C Harte-Hargrove, Diana L Dow-Edwards
Dec 10, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stephanie M GorkaChristine A Rabinak
Sep 20, 2011·Pharmacology & Therapeutics·Andrew J HillGary J Stephens
Feb 11, 2010·Neuroscience and Biobehavioral Reviews·R SmieskovaS J Borgwardt
Feb 2, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Marc WalterStefan J Borgwardt
Aug 20, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Margaret Haney, A Eden Evins
Sep 16, 2015·Psychological Medicine·E Appiah-KusiS Bhattacharyya
Jul 14, 2011·British Journal of Pharmacology·Ethan B Russo
Oct 26, 2012·Journal of Clinical Pharmacy and Therapeutics·J A S CrippaA W Zuardi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Related Papers

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
K Luan PhanHarriet de Wit
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Sagnik BhattacharyyaPhilip K McGuire
Human Psychopharmacology
José Alexandre S CrippaPaolo Fusar-Poli
© 2021 Meta ULC. All rights reserved